BOSTON, Mass. (


) -- A calendar of important, potentially stock-moving biotech events for May:

May 1-6

Digestive Disease Week annual meeting.

May 3-6

BIO International Convention.

May 3-7

Amylin Pharmaceuticals

( AMLN),

Eli Lilly

(LLY) - Get Report



(ALKS) - Get Report

expected to hear back from FDA on new approval decision date for the diabetes drug Bydureon. Class 1 response means June date; Class 2 response means October date.

Biotech Busts and Breakthroughs (Forbes)

May 4

FDA approval decision date for



Esbriet (pirfenidone) for treatment of idiopathic pulmonary fibrosis.

Cleveland BioLabs

(CBLI) - Get Report

analyst/investor meeting.

Vanda Pharmaceuticals

(VNDA) - Get Report

first-quarter earnings, including update on commercial launch of the schizophrenia drug Fanapt.

May 5

Allos Therapeutics

( ALTH) first-quarter earnings, including update on commercial launch of the lymphoma drug Folotyn.

King Pharmaceuticals

( KG) first quarter earnings: Will King update investors on its pain drug partnership with

Acura Pharmaceuticals



May 6


( GENZ) analyst/investors meeting.

FDA advisory panel to review

Questcor Pharmaceuticals'


Acthar for infantile spasms. The FDA's briefing documents should be posted to the agency's web site on May 4 or May 5.



first-quarter earnings.

May 7

Mike Huckman's last day at


. Good luck, Mike!

Cytori Therapeutics


reports full, six-month results from Apollo trial (heart attack) and preliminary, six-month results from Precise (chronic ischemia) trial at Stem Cell Therapy and Cardiovascular Innovation conference.

May 11


(MRK) - Get Report

analyst/investor meeting.

May 14


(ATHX) - Get Report

investor/analyst meeting.

Cell Therapeutics

(CTIC) - Get Report

rescheduled shareholder meeting.

Patent expiration for Taxotere, marketed by


(SNY) - Get Report


May 14-19

American Pain Society annual meeting.

May 14-19

American Thoracic Society annual meeting.

May 15-19

American College of Obstetricians and Gynecologists annual meeting.

May 19-23

American Society of Gene and Cell Therapy

May 22-27

American Psychiatric Association annual meeting.

May 29 - June 3

American Urological Association annual meeting: The medical meeting debut of



Provenge as a fully approved prostate cancer immunotherapy!

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on



Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.